Literature DB >> 14756581

Malformation rates in children of women with untreated epilepsy: a meta-analysis.

Shawn Fried1, Eran Kozer, Irena Nulman, Thomas R Einarson, Gideon Koren.   

Abstract

BACKGROUND: It is widely quoted that women with epilepsy have a higher than baseline risk for giving birth to a child with malformations, independent of the effects of antiepileptic drugs.
OBJECTIVE: To determine, based on available evidence, if epilepsy per se represents a teratogenic risk. To systematically review all studies investigating the occurrence of major malformation rates among children of treated or untreated women with epilepsy and non-exposed controls who do not have epilepsy.
METHODS: A meta-analysis, using a random effects model, was conducted of all cohort and case-control studies reporting malformation rates in children of women with epilepsy exposed or unexposed to antiepileptic drugs compared with that of children of nonepileptic women. Medline (1966-2001), EMBASE, the Cochrane database as well as REPROTOX (an information system on environmental hazards to human reproduction and development) databases were accessed.
RESULTS: We found ten studies reporting results of untreated epilepsy (n = 400) and their non-epileptic healthy controls (n = 2492). Nine out of ten studies also reported results on 1443 patients exposed to antiepileptic drugs and their 2526 unexposed healthy controls. The risk for congenital malformations in the offspring of women with untreated epilepsy was not higher than among nonepileptic controls (odds ratio [OR] = 1.92; 95% CI 0.92-4.00). There was evidence of publication bias, thus with bias removed the OR was 0.99 (95% CI 0.49-2.01). In contrast, the offspring of epileptic women who received antiepileptic drugs had higher incidences of malformation than controls (OR 3.26; 95% CI 2.15-4.93).
CONCLUSION: Our study does not support the commonly held view that epilepsy per se represents a teratogenic risk. Our study suggests that this view is the result of a publication bias, with several small (< 100 participants) positive studies leading to a premature conclusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14756581     DOI: 10.2165/00002018-200427030-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  21 in total

1.  Major and minor birth malformations and antiepileptic drugs.

Authors:  S Koch; G Lösche; E Jager-Romän; S Jakob; D Rating; A Deichl; H Helge
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

2.  Maternal epilepsy and abnormalities of the fetus and newborn.

Authors:  B D Speidel; S R Meadow
Journal:  Lancet       Date:  1972-10-21       Impact factor: 79.321

3.  Anticonvulsants and congenital malformations.

Authors:  S S Jick; B Z Terris
Journal:  Pharmacotherapy       Date:  1997 May-Jun       Impact factor: 4.705

4.  Intelligence and physical features of children of women with epilepsy.

Authors:  L B Holmes; P B Rosenberger; E A Harvey; S Khoshbin; L Ryan
Journal:  Teratology       Date:  2000-03

Review 5.  Treatment of epilepsy in pregnancy.

Authors:  I Nulman; D Laslo; G Koren
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 6.  Women with epilepsy. Reproduction and effects of pregnancy on epilepsy.

Authors:  O Devinsky; M S Yerby
Journal:  Neurol Clin       Date:  1994-08       Impact factor: 3.806

7.  Antiepileptic medication in pregnancy: late effects on the children's central nervous system development.

Authors:  M C van der Pol; M Hadders-Algra; H J Huisjes; B C Touwen
Journal:  Am J Obstet Gynecol       Date:  1991-01       Impact factor: 8.661

Review 8.  Pregnancy, teratogenesis, and epilepsy.

Authors:  M S Yerby
Journal:  Neurol Clin       Date:  1994-11       Impact factor: 3.806

9.  The teratogenicity of hydantoins and barbiturates in humans, with considerations on the etiology of malformations and cerebral disturbances in the children of epileptic parents.

Authors:  F Majewski; M Steger; B Richter; J Gill; F Rabe
Journal:  Int J Biol Res Pregnancy       Date:  1981

10.  [Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development].

Authors:  S Koch; I Göpfert-Geyer; E Jäger-Roman; S Jakob; H Huth; A Hartmann; D Rating; H Helge
Journal:  Dtsch Med Wochenschr       Date:  1983-02-18       Impact factor: 0.628

View more
  29 in total

1.  Using current evidence in selecting antiepileptic drugs for use during pregnancy.

Authors:  Page B Pennell
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

Review 2.  In utero exposure to antiepileptic drugs: teratogenicity and neonatal morbidity.

Authors:  Tarannum Musvee Lateef; Karin B Nelson
Journal:  Curr Neurol Neurosci Rep       Date:  2007-03       Impact factor: 5.081

Review 3.  Epilepsy in pregnancy.

Authors:  Torbjörn Tomson; Vilho Hiilesmaa
Journal:  BMJ       Date:  2007-10-13

4.  Use of antiepileptic medications in pregnancy in relation to risks of birth defects.

Authors:  Martha M Werler; Katherine A Ahrens; Jaclyn L F Bosco; Allen A Mitchell; Marlene T Anderka; Suzanne M Gilboa; Lewis B Holmes
Journal:  Ann Epidemiol       Date:  2011-11       Impact factor: 3.797

5.  Alteration of bioelectrically-controlled processes in the embryo: a teratogenic mechanism for anticonvulsants.

Authors:  Sonia Hernández-Díaz; Michael Levin
Journal:  Reprod Toxicol       Date:  2014-05-06       Impact factor: 3.143

Review 6.  Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies.

Authors:  Ryan Banach; Radinka Boskovic; Thomas Einarson; Gideon Koren
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

7.  Use of topiramate in pregnancy and risk of oral clefts.

Authors:  Andrea V Margulis; Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Murray A Mittleman; Robert J Glynn; Sonia Hernandez-Diaz
Journal:  Am J Obstet Gynecol       Date:  2012-07-16       Impact factor: 8.661

Review 8.  Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.

Authors:  C L Harden; K J Meador; P B Pennell; W A Hauser; G S Gronseth; J A French; S Wiebe; D Thurman; B S Koppel; P W Kaplan; J N Robinson; J Hopp; T Y Ting; B Gidal; C A Hovinga; A N Wilner; B Vazquez; L Holmes; A Krumholz; R Finnell; D Hirtz; C Le Guen
Journal:  Neurology       Date:  2009-04-27       Impact factor: 9.910

Review 9.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect.

Authors:  Orna Diav-Citrin; Svetlana Shechtman; Benjamin Bar-Oz; Dana Cantrell; Judy Arnon; Asher Ornoy
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.